Afficher la notice abrégée

Concerns about pharmacokinetic (PK) and pharmacokinetic-pharmacodynamic (PK-PD) studies in the new therapeutic area of COVID-19 infection

dc.rights.licenseopenen_US
dc.contributor.authorVENISSE, N.
dc.contributor.authorPEYTAVIN, G.
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorBOUCHET, Stephane
dc.contributor.authorGAGNIEU, M. C.
dc.contributor.authorGARRAFFO, R.
dc.contributor.authorGUILHAUMOU, R.
dc.contributor.authorSOLAS, C.
dc.date.accessioned2021-02-19T15:27:55Z
dc.date.available2021-02-19T15:27:55Z
dc.date.issued2020
dc.identifier.issn0166-3542 (Print) 0166-3542en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/26304
dc.description.abstractEnIn the context of the COVID-19 pandemic, several drugs have been repurposed as potential candidates for the treatment of COVID-19 infection. While preliminary choices were essentially based on in vitro potency, clinical translation into effective therapies may be challenging due to unfavorable in vivo pharmacokinetic properties at the doses chosen for this new indication of COVID-19 infection. However, available pharmacokinetic and pharmacokinetic-pharmacodynamic studies suffer from severe limitations leading to unreliable conclusions, especially in term of dosing optimization. In this paper we propose to highlight these limitations and to identify some of the major requirements that need to be addressed in designing PK and PK-PD studies in this era of COVID. A special attention should be paid to pre-analytical and analytical requirements and to the proper collection of covariates affecting dose-exposure relationships (co-medications, use of specific organ support techniques and other clinical and para-clinical data). We also promote the development of population PK and PK-PD models specifically dedicated to COVID-19 patients since those previously developed for other diseases (SEL, malaria, HIV) and clinical situations (steady-state, non-ICU patients) are not representative of severe patients. Therefore, implementation of well-designed PK and PD studies targeted to COVID-19 patients is urgently needed. For that purpose we call for multi-institutional collaborative work and involvement of clinical pharmacologists in multidisciplinary research consortia.
dc.language.isoENen_US
dc.subjectPharmacoEpi-Drugs
dc.title.enConcerns about pharmacokinetic (PK) and pharmacokinetic-pharmacodynamic (PK-PD) studies in the new therapeutic area of COVID-19 infection
dc.title.alternativeAntiviral Resen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1016/j.antiviral.2020.104866en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed32659293en_US
bordeaux.journalAntiviral Researchen_US
bordeaux.page104866en_US
bordeaux.volume181en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - U1219en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.teamPharmacoEpi-Drugsen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-03147202
hal.version1
hal.date.transferred2021-02-19T15:27:58Z
hal.exporttrue
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Antiviral%20Research&rft.date=2020&rft.volume=181&rft.spage=104866&rft.epage=104866&rft.eissn=0166-3542%20(Print)%200166-3542&rft.issn=0166-3542%20(Print)%200166-3542&rft.au=VENISSE,%20N.&PEYTAVIN,%20G.&BOUCHET,%20Stephane&GAGNIEU,%20M.%20C.&GARRAFFO,%20R.&rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée